A new era of cell therapy has well and truly arrived with the iPSC field setting a trailblazing fire with its potential to develop fully scalable, off-the-shelf cell lines reducing the cost of ...
Dr. Dina Radenkovic: We’re the first people pioneering iPSC therapy for use in women’s health and IVF. We’re also the first iPSC in Phase III in the US. When there is no precedent, you’re chartering ...
A team of Japanese researchers reports that two out of four patients who received stem cell transplants showed improvements in motor function, marking a potential breakthrough in the treatment of ...
Evotec has built up a cell therapy portfolio consisting of diverse iPSC-derived cell types. Programs continue to advance with the end-to-end platform providing discovery, preclinical ...
Century Therapeutics, Inc. (NASDAQ: IPSC) outlined a strategic pipeline re-prioritization and shared its financial results ...
Century Therapeutics (NASDAQ:IPSC – Free Report) had its target price reduced by Chardan Capital from $11.00 to $7.00 in a ...
application next year to bring its autologous iPSC-derived therapy into clinical trials. This transformative approach addresses an urgent unmet need, potentially restoring function for millions of ...
Century Therapeutics (NASDAQ:IPSC – Free Report) had its target price decreased by Guggenheim from $12.00 to $5.00 in a research note published on Friday morning,Benzinga reports. Guggenheim currently ...
GERMANTOWN, MARYLAND / ACCESS Newswire / March 4, 2025 / uBriGene Biosciences (uBriGene), a leading cell and gene therapy CDMO, is pleased to announce the submission of its Drug Master File (DMF ...
The IIT, which is sponsored by the Friedrich-Alexander University Erlangen-Nürnberg, represents the first evaluation by the internationally recognized Schett/Mackensen group of an allogeneic ...
As iPSC-derived NK cells express high levels of ... Cytovia could transform cancer care through a range of single agent and combination therapy options tailored to the health status of individual ...